The University of Texas MD Anderson Cancer Center (US)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
238
Publications
5810
Citations
286399
i10-index
2645
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Efficacy and Safety of a Specific Inhibitor of the... | 2001 | 5283 |
The 5th edition of the World Health Organization C... | 2022 | 4215 |
Imatinib Compared with Interferon and Low-Dose Cyt... | 2003 | 3593 |
Five-Year Follow-up of Patients Receiving Imatinib... | 2006 | 3498 |
Revised International Prognostic Scoring System fo... | 2012 | 3187 |
Activity of a Specific Inhibitor of the BCR-ABL Ty... | 2001 | 2730 |
Blinatumomab versus Chemotherapy for Advanced Acut... | 2017 | 2149 |
A Double-Blind, Placebo-Controlled Trial of Ruxoli... | 2012 | 2100 |
European LeukemiaNet recommendations for the manag... | 2013 | 1991 |
Venetoclax combined with decitabine or azacitidine... | 2018 | 1824 |
Hagop M. Kantarjian is a researcher with 5810 publications and 286399 citations. They are affiliated with The University of Texas MD Anderson Cancer Center. Their research focuses on . With an h-index of 238, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Hagop M. Kantarjian and 250M+ other papers.
Citations per publication by year